Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management.
Couture F, Turner AR, Melosky B, et al.
Oncologist 2005;10(1):63-71.
Review by
A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
Schwartzberg LS, Yee LK, Senecal FM, et al.
Oncologist 2004;9(6):696-707.
Review by
Recombinant activated factor VII in patients with cancer and hemorrhagic disseminated intravascular coagulation.
Sallah S, Husain A, Nguyen NP
Blood Coagul Fibrinolysis 2004;15(7):577-582.
Review by M. Aldouri
Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: Results of a randomized, controlled trial.
Iconomou G, Koutras A, Rigopoulos A, Vagenakis AG, Kalofonos HP
J Pain Symptom Manage 2003;25(6):512-518.
Review by
Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy – results of a randomized trial.
Glossmann JP, Engert A, Wassmer G, et al.
Ann Hematol 2003;82(8):469-475.
Review by Henry DH
Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production.
Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B
Br J Haematol 2003;122(3):386-393.
Review by
Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study.
Hedenus M, Adriansson M, Miguel JS, et al.
Br J Haematol 2003;122(3):394-403.
Review by
Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy.
This is a well done study of anemic cancer patients on cisplatin chemotherapy that documents nicely that the best predictor of an ultimate good response... Read More
Recombinant human erythropoietin in pediatric oncology: a review.
Feusner J, Hastings C
Med Pediatr Oncol 2002;39(4):463-468.
Review by Ford PA
Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.
Vansteenkiste J, Pirker R, Massuti B, et al.
J Natl Cancer Inst 2002;94(16):1211-1220.
Review by Ford PA
Exposure to allogeneic plasma and risk of postoperative pneumonia and/or wound infection in coronary artery bypass graft surgery.
Vamvakas EC, Carven JH
Transfusion 2002;42(1):107-113.
Review by Kretschmer V
High intensity focused ultrasound: A method of hemostasis.
This inovative work bears watching. Potential applications include minimally invasive, i.e., laparoscopic, approaches to control of traumatic liver injury. – R. K. Spence.
NATA: Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis
MISSION: Providing a multidisciplinary forum for dialogue between haematologists, transfusion medicine specialists, anaesthesiologists, intensive care and emergency physicians, surgeons, perfusionists, nurses, biomedical scientists and other healthcare professionals.
Sitemap
Contact us
- secretary@nataonline.com
-
NATA
Rue de l’Industrie 24
1040 Bruxelles - VAT: 0781668659